Works matching DE "CD22 antigen"

Results: 22

N-Linked Glycosylation Regulates CD22 Organization and Function.

Published in:

Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00699

By:

Wasim, Laabiah;
Buhari, Fathima Hifza Mohamed;
Yoganathan, Myuran;
Sicard, Taylor;
Ereño-Orbea, June;
Julien, Jean-Philippe;
Treanor, Bebhinn

Publication type:

Article

Profiling the Atlantic Salmon IgM+ B Cell Surface Proteome: Novel Information on Teleost Fish B Cell Protein Repertoire and Identification of Potential B Cell Markers.

Published in:

Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00037

By:

Peñaranda, Ma. Michelle D.;
Jensen, Ingvill;
Tollersrud, Linn G.;
Bruun, Jack-Ansgar;
Jørgensen, Jorunn B.

Publication type:

Article

CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

Published in:

Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.00820

By:

Matsubara, Naoko;
Imamura, Akihiro;
Yonemizu, Tatsuya;
Akatsu, Chizuru;
Yang, Hongrui;
Ueki, Akiharu;
Watanabe, Natsuki;
Abdu-Allah, Hajjaj;
Numoto, Nobutaka;
Takematsu, Hiromu;
Kitazume, Shinobu;
Tedder, Thomas F.;
Marth, Jamey D.;
Ito, Nobutoshi;
Ando, Hiromune;
Ishida, Hideharu;
Kiso, Makoto;
Tsubata, Takeshi

Publication type:

Article

A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.

Published in:

AMB Express, 2017, v. 7, n. 1, p. 1, doi. 10.1186/s13568-017-0410-5

By:

Agha Amiri, Solmaz;
Shahhosseini, Soraya;
Zarei, Najmeh;
Khorasanizadeh, Dorsa;
Aminollahi, Elahe;
Rezaie, Faegheh;
Zargari, Mehryar;
Azizi, Mohammad;
Khalaj, Vahid

Publication type:

Article

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

Published in:

Molecular Medicine, 2016, v. 22, n. 1, p. 632, doi. 10.2119/molmed.2015.00210

By:

Satake, Noriko;
Duong, Connie;
Yoshida, Sakiko;
Oestergaard, Michael;
Chen, Cathy;
Peralta, Rachael;
Guo, Shuling;
Seth, Punit P;
Li, Yueju;
Beckett, Laurel;
Chung, Jong;
Nolta, Jan;
Nitin, Nitin;
Tuscano, Joseph M

Publication type:

Article

High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.

Published in:

Applied Microbiology & Biotechnology, 2014, v. 98, n. 24, p. 10023, doi. 10.1007/s00253-014-6071-2

By:

Zarei, Najmeh;
Vaziri, Behrouz;
Shokrgozar, Mohammad;
Mahdian, Reza;
Fazel, Ramin;
Khalaj, Vahid

Publication type:

Article

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.

Published in:

Toxins, 2018, v. 10, n. 5, p. 210, doi. 10.3390/toxins10050210

By:

Müller, Fabian;
Cunningham, Tyler;
Beers, Richard;
Bera, Tapan K.;
Wayne, Alan S.;
Pastan, Ira

Publication type:

Article

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

Published in:

European Journal of Haematology, 2017, v. 98, n. 5, p. 425, doi. 10.1111/ejh.12862

By:

Thota, Swapna;
Advani, Anjali

Publication type:

Article

CD8+CD122+ T-cells: a newly emerging regulator with central memory cell phenotypes.

Published in:

Frontiers in Immunology, 2015, v. 6, p. 1, doi. 10.3389/fimmu.2015.00494

By:

Junfeng Liu;
Dacan Chen;
Nie, Golay D.;
Zhenhua Dai

Publication type:

Article

CD22 is required for formation of memory B cell precursors within germinal centers.

Published in:

PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0174661

By:

Chappell, Craig P.;
Draves, Kevin E.;
Clark, Edward A.

Publication type:

Article

Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker.

Published in:

Biotechnology & Applied Biochemistry, 2018, v. 65, n. 5, p. 718, doi. 10.1002/bab.1654

By:

Faraji, Fatemeh;
Tajik, Nader;
Behdani, Mahdi;
Shokrgozar, Mohammad Ali;
Zarnani, Amir Hassan;
Shahhosseini, Fatemeh;
Habibi‐Anbouhi, Mahdi

Publication type:

Article

Lumoxiti a New Treatment Approved for Patients with Hairy-Cell Leukemia.

Published in:: Oncology Practice Management, 2018, v. 8, n. 10, p. 22
Publication type:: Article

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.

Published in:

2015

By:

Weber, Tobias;
Mavratzas, Athanasios;
Kiesgen, Stefan;
Haase, Stephanie;
Bötticher, Benedikt;
Exner, Evelyn;
Mier, Walter;
Grosse-Hovest, Ludger;
Jäger, Dirk;
Arndt, Michaela A. E.;
Krauss, Jürgen;
Bötticher, Benedikt;
Jäger, Dirk

Publication type:

journal article

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.

Published in:: Journal of Hematology & Oncology, 2011, v. 4, n. 1, p. 49, doi. 10.1186/1756-8722-4-49
Publication type:: Article

CD22ΔE12 as a molecular target for RNAi therapy.

Published in:

British Journal of Haematology, 2015, v. 169, n. 3, p. 401, doi. 10.1111/bjh.13306

By:

Uckun, Fatih M.;
Ma, Hong;
Cheng, Jianjun;
Myers, Dorothea E.;
Qazi, Sanjive

Publication type:

Article

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Published in:

British Journal of Haematology, 2014, v. 165, n. 4, p. 504, doi. 10.1111/bjh.12778

By:

Advani, Anjali S.;
McDonough, Shannon;
Coutre, Steven;
Wood, Brent;
Radich, Jerald;
Mims, Martha;
O'Donnell, Margaret;
Elkins, Stephanie;
Becker, Michael;
Othus, Megan;
Appelbaum, Frederick R.

Publication type:

Article

SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.

Published in:

Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00020

By:

Etienne, Floriane;
Berthaud, Maxime;
Nguyen, Frédérique;
Bernardeau, Karine;
Maurel, Catherine;
Bodet-Milin, Caroline;
Diab, Maya;
Abadie, Jérôme;
Gouilleux-Gruart, Valérie;
Vidal, Aurélien;
Bourgeois, Mickaël;
Chouin, Nicolas;
Ibisch, Catherine;
Davodeau, François

Publication type:

Article

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Published in:

2018

By:

Pirosa, Maria Cristina;
Leotta, Salvatore;
Cupri, Alessandra;
Stella, Stefania;
Martino, Enrica Antonia;
Scalise, Luca;
Sapienza, Giuseppe;
Calafiore, Valeria;
Mauro, Elisa;
Spadaro, Andrea;
Vigneri, Paolo;
Di Raimondo, Francesco;
Milone, Giuseppe

Publication type:

Case Study

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia.

Published in:

Blood & Lymphatic Cancer: Targets & Therapy, 2014, v. 4, p. 1, doi. 10.2147/BLCTT.S49048

By:

Thomas, Xavier

Publication type:

Article

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.

Published in:

Pharmaceutics, 2018, v. 10, n. 2, p. 50, doi. 10.3390/pharmaceutics10020050

By:

Mittal, Nivesh K.;
Mandal, Bivash;
Balabathula, Pavan;
Setua, Saini;
Janagam, Dileep R.;
Lothstein, Leonard;
Thoma, Laura A.;
Wood, George C.

Publication type:

Article

Generation of Anti-Idiotype scFv for Pharmacokinetic Measurement in Lymphoma Patients Treated with Chimera Anti-CD22 Antibody SM03.

Published in:

PLoS ONE, 2014, v. 9, n. 5, p. 1, doi. 10.1371/journal.pone.0096697

By:

Zhao, Qi;
Wong, Pui-Fan;
Lee, Susanna S. T.;
Leung, Shui-On;
Cheung, Wing-Tai;
Wang, Jun-Zhi

Publication type:

Article

CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.

Published in:

Glycobiology, 2014, v. 24, n. 9, p. 807, doi. 10.1093/glycob/cwu066

By:

Nitschke, Lars

Publication type:

Article

Works matching DE "CD22 antigen"

N-Linked Glycosylation Regulates CD22 Organization and Function.

Profiling the Atlantic Salmon IgM<sup>+</sup> B Cell Surface Proteome: Novel Information on Teleost Fish B Cell Protein Repertoire and Identification of Potential B Cell Markers.

CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

CD8<sup>+</sup>CD122<sup>+</sup> T-cells: a newly emerging regulator with central memory cell phenotypes.

CD22 is required for formation of memory B cell precursors within germinal centers.

Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker.

Lumoxiti a New Treatment Approved for Patients with Hairy-Cell Leukemia.

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.

CD22ΔE12 as a molecular target for RNAi therapy.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia.

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.

Generation of Anti-Idiotype scFv for Pharmacokinetic Measurement in Lymphoma Patients Treated with Chimera Anti-CD22 Antibody SM03.

CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.